Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous terlipressin infusion versus weekly albumin in decompensated cirrhosis with ascites
ACTRN12624000903583Phase 3Not yet recruiting
- Sponsor
- Austin Health
- Start
- Jul 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of terlipressin and albumin (human) in Cirrhosis (2 arms), sponsored by Austin Health. Primary endpoint: Time to major decompensating liver event. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
terlipressinalbumin (human)
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on ACTRN12624000903583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000903583.